Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer

Lupus. 2021 Mar;30(3):531-533. doi: 10.1177/0961203320983448. Epub 2021 Jan 6.

Authors

Thilo Gambichler¹, Martin Doerler¹, Christina H Scheel¹

Affiliation

¹ Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

PMID: 33407044
DOI: 10.1177/0961203320983448

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy*
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Humans
Immune Checkpoint Inhibitors / adverse effects*
Immune Checkpoint Inhibitors / therapeutic use
Lung Neoplasms / drug therapy*
Lupus Erythematosus, Cutaneous / chemically induced*
Lupus Erythematosus, Cutaneous / pathology
Lupus Erythematosus, Cutaneous / therapy
Male
Middle Aged

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
pembrolizumab